{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T04:38:22.242084+00:00","company":{"ticker":"CGEM","cik":1789972,"company_name":"Cullinan Therapeutics, Inc."},"pagination":{"limit":100,"returned":9,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"b7f8864803bff4fb25642459b3563a3d4451f477","cik":1789972,"ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $49.7 million for the first quarter of 2026","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":null},"claim":"Cullinan Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $49.7 million for the first quarter of 2026.","evidence_excerpt":"On May 7, 2026, Cullinan Therapeutics, Inc. (the \"Company\") announced its financial results for the three months ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-210290","anchor_url":"https://secwatch.observer/filing/0001193125-26-210290#claim-b7f8864803bff4fb25642459b3563a3d4451f477","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1789972/000119312526210290/0001193125-26-210290-index.htm"},{"fact_type":"earnings_release","fact_key":"d73ef739f3bde787b5fae8510d8ec33a6e63a83b","cik":1789972,"ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss (before items attributable to noncontrolling interest) for the first quarter of 2024 was $37.3 million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-15","result_type":"reported_results","revenue_text":null},"claim":"Cullinan Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss (before items attributable to noncontrolling interest) for the first quarter of 2024 was $37.3 million.","evidence_excerpt":"Cullinan Therapeutics, Inc. (the \"Company\") announced its financial results for the quarter ended March 31, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-060481","anchor_url":"https://secwatch.observer/filing/0000950170-24-060481#claim-d73ef739f3bde787b5fae8510d8ec33a6e63a83b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/0000950170-24-060481-index.htm"},{"fact_type":"executive_change","fact_key":"bd5fb882af","cik":1789972,"ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-06-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Thomas Ebeling resigned as Director at Cullinan Therapeutics, Inc..","evidence_excerpt":"Thomas Ebeling notified the Board of his intention to serve out his current term and resign as a director effective as of June 26, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-060481","anchor_url":"https://secwatch.observer/filing/0000950170-24-060481#claim-bd5fb882af","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/0000950170-24-060481-index.htm"},{"fact_type":"executive_change","fact_key":"31b771d8b1","cik":1789972,"ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-05-15","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"David Meek was appointed as Class I Director at Cullinan Therapeutics, Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of the Company appointed David Meek as a Class I director, effective May 15, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000950170-24-060481","anchor_url":"https://secwatch.observer/filing/0000950170-24-060481#claim-31b771d8b1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/0000950170-24-060481-index.htm"},{"fact_type":"executive_change","fact_key":"140aa04d19","cik":1789972,"ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2024-04-29T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-04-29","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Mary Kay Fenton was appointed as Chief Financial Officer at Cullinan Therapeutics, Inc..","evidence_excerpt":"On April 29, 2024, Cullinan Therapeutics, Inc. (the “Company”) announced the hiring and appointment of Mary Kay Fenton as the Company’s Chief Financial Officer, effective immediately.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000950170-24-049436","anchor_url":"https://secwatch.observer/filing/0000950170-24-049436#claim-140aa04d19","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024049436/0000950170-24-049436-index.htm"},{"fact_type":"governance_change","fact_key":"9caf408d55111302b41a15823a7ee07c07dc9ed8","cik":1789972,"ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2024-04-16T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2024-04-15","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws solely to reflect the name change."},"claim":"Cullinan Therapeutics, Inc.: Amended and restated bylaws solely to reflect the name change (effective 2024-04-15).","evidence_excerpt":"the Board also approved an amendment and restatement of the Company’s Second Amended and Restated Bylaws solely to reflect the Name Change (as amended and restated, the “ Third Amended and Restated Bylaws ”) effective as of April 15, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-044593","anchor_url":"https://secwatch.observer/filing/0000950170-24-044593#claim-9caf408d55111302b41a15823a7ee07c07dc9ed8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/0000950170-24-044593-index.htm"},{"fact_type":"governance_change","fact_key":"86ab9116b16ca97713d7a702ad556c56b8a38bdf","cik":1789972,"ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2024-04-16T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2024-04-15","item_codes_triggered":["5.03"],"summary_text":"Amended certificate of incorporation to change company name from Cullinan Oncology, Inc. to Cullinan Therapeutics, Inc."},"claim":"Cullinan Therapeutics, Inc.: Amended certificate of incorporation to change company name from Cullinan Oncology, Inc. to Cullinan Therapeutics, Inc (effective 2024-04-15).","evidence_excerpt":"Effective as of 9:47 A.M., Eastern Time on April 15, 2024, the Company amended its Second Amended and Restated Certificate of Incorporation, as amended (the “ Certificate of Incorporation ”), to effect a change of the Company’s name from “Cullinan Oncology, Inc.” to “Cullinan Therapeutics, Inc.” (the “ Name Change ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-044593","anchor_url":"https://secwatch.observer/filing/0000950170-24-044593#claim-86ab9116b16ca97713d7a702ad556c56b8a38bdf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/0000950170-24-044593-index.htm"},{"fact_type":"material_agreement","fact_key":"5837751a3cb2a5fc83a0bc3cc6e72f4753da8acc","cik":1789972,"ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2024-04-16T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Stock Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain institutional accredited investors","effective_date":"2024-04-15","item_codes_triggered":["1.01"],"value_text":"$280M gross proceeds for sale of 14,421,070 shares at $19.00/share and 315,790 pre-funded warrants a"},"claim":"Cullinan Therapeutics, Inc. entered into Stock Purchase Agreement with certain institutional accredited investors valued at $280M gross proceeds for sale of 14,421,070 shares at $19.00/share and 315,790 pre-funded warrants a (effective 2024-04-15).","evidence_excerpt":"On April 15, 2024, Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc.) (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain institutional accredited investors named therein (each, a “ Purchaser ” and collectively, the “ Purchasers ”).","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0000950170-24-044593","anchor_url":"https://secwatch.observer/filing/0000950170-24-044593#claim-5837751a3cb2a5fc83a0bc3cc6e72f4753da8acc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024044593/0000950170-24-044593-index.htm"},{"fact_type":"earnings_release","fact_key":"616a4a325dbda65c3012e7cff516d47c3d69556e","cik":1789972,"ticker":"CGEM","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter and year ended December 31, 2023","report_date":"2024-03-14","result_type":"reported_results","revenue_text":null},"claim":"Cullinan Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"On March 14, 2024, Cullinan Oncology, Inc. announced its financial results for the quarter and year ended December 31, 2023.","confidence":0.7,"filing_url":"https://secwatch.observer/filing/0000950170-24-031140","anchor_url":"https://secwatch.observer/filing/0000950170-24-031140#claim-616a4a325dbda65c3012e7cff516d47c3d69556e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1789972/000095017024031140/0000950170-24-031140-index.htm"}]}